Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2

NCT05301010 is registered in ClinicalTrials.gov with Nanogen Pharmaceutical Biotechnology Joint Stock Company as lead sponsor.

NCT NCT05301010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05301010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2
Lead sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Phase
Phase 3
Overall status
Completed
Start date
February 2, 2018
Completion date
February 19, 2021
Enrollment
128 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, breast cancer metastatic, breast cancer recurrent